Abbott Laboratories (ABT) FY2025 10-K Annual Report
Abbott Laboratories (ABT) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 20, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Abbott Laboratories FY2025 10-K Analysis
Business Overview
- • Core business model centered on healthcare products and medical technologies, with no new product lines detailed in 2026 filing
- • Notable new segment emphasis: merger agreement dated November 19, 2025 with Exact Sciences Corporation
- • Strategic shift: Amended and restated By-Laws effective December 12, 2025, indicating governance updates
- • Quantitative metric: Allowances for doubtful accounts and product returns increased to $490M in 2025 from $439M in 2024
- • Most noteworthy fact: Inclusion of significant merger-related documents and ongoing update of compensation and governance policies in 2026 Proxy Statement
Management Discussion & Analysis
- • Revenue $44.2B in 2025, up 5.7% YoY excluding foreign exchange impact
- • Operating margin 18.2% in 2025 vs 16.3% in 2024; Medical Devices margin 33.7% vs 32.4%
- • Best segment: Medical Devices sales up 12.6% (to approx. $19.9B); worst: Diagnostics sales down 4.3% with margin decline to 19.5% from 24.4%
- • Cash and short-term investments $8.9B; long-term debt $12.9B; dividends $4.1B, increased 7.1% to $2.40/share in 2025
- • 2026 outlook: focus on growth in diagnostics (Alinity platform), medical devices, nutrition product innovation and emerging market pharmaceutical expansion
Risk Factors
- • IRS tax disputes over 2017-2020 SNODs totaling $1.05B contested, involving income reallocation between U.S. and foreign affiliates
- • Malaysian tax authorities assessed $413M capital gains tax on 2023 intercompany share sale; Penang High Court upheld, Abbott appealed in 2025
- • Supply chain tariffs and foreign exchange fluctuations increased costs, partially offsetting margin improvement which led to only a 52.6% gross margin in 2025
- • Competitive pressure from biosimilars and off-patent medicines expansion in emerging markets challenges Established Pharmaceuticals segment growth
- • Debt maturity exposure with $3.0B of $12.9B total debt due in 2026, plus $20B unsecured bridge loan commitment related to Exact Sciences acquisition
Abbott Laboratories FY2025 Key Financial MetricsXBRL
Revenue
$44.3B
▲ +5.7% YoY
Net Income
$6.5B
▼ -51.3% YoY
Operating Margin
18.2%
▲ +190bp YoY
Net Margin
14.7%
▼ -1723bp YoY
ROE
12.5%
▼ -1560bp YoY
Total Assets
$86.7B
▲ +6.5% YoY
EPS (Diluted)
$3.72
▼ -51.3% YoY
Operating Cash Flow
$9.6B
▲ +11.8% YoY
Source: XBRL data from Abbott Laboratories FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Abbott Laboratories
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.